glp 1 drugs and parkinson's disease GLP-1 Disease: New Clues in Neurodegeneration The most extensive research to-date
Description
That study enrolled 3,417 adults with obesity or overweight and without type 2 diabetes, and showed a mean weight loss of 22.7% at 68 weeks in patients who remained on treatment
Genomic instability and DNA damage response (DDR) Genomic instability, which involves damage to DNA and mutations, contributes to the acceleration of aging
And annual revenue from global obesity drug sales could quadruple to $120 billion by 2030, according to Bloomberg Intelligence
Related articles: [1]
Records were initially screened at title and abstract level, and potentially eligible records were examined in full text with reasons for exclusion being recorded
Long interested in Holst's work, in 1990 Novo Nordisk recruited his colleague Schwartz to develop small molecules able to activate the GLP receptor in the pancreas (Molteni, Chen)
